Meeting
2014 ASCO Annual Meeting
Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Authors
Saul E. Rivkin
Marsha Rivkin Center for Ovarian Cancer Research, Seattle, WA
Saul E. Rivkin , Desiree Iriarte , Heather Sloan , Cara Wiseman , James Moon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01650376
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5527)
DOI
10.1200/jco.2014.32.15_suppl.5527
Abstract #
5527
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
First Author: Saul E. Rivkin
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2020 ASCO Virtual Scientific Program
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
First Author: Elena Ioana Braicu
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong